Influenza (seasonal)

Sanofi promises 7% vax sales growth for 2015, despite rocky Q1

Sanofi says it's poised to repeat the 7% growth its vaccines unit saw last year. But after battling through a slow quarter for influenza vaccine sales, it'll have some catching up to do for the remainder of the year if it wants to make that happen.
Thanks to two strain changes in the Southern Hemisphere, the company saw a delayed flu campaign and, as a result, a 4.6% drop in overall vaccines sales from last year's first quarter. Despite the slow start, though, Sanofi ($SNY) execs have pegged the vaccines unit to deliver a repeat 7% jump for the year.

National Adult and Influenza Immunization Summit Meeting

Hosted by the National Adult and Influenza Immunization Summit 

From the National Adult and Influenza Immunization Summit website:

Preliminary Meeting Details
Attendees can pick-up their registration packages on May 11 (3:00 p.m.–6:00 p.m.) or all day during the conference in the International Ballroom Lobby – LL1.

Day 1—May 12: Adult Immunization


China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies' (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China's human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

Potency worries prompt GSK flu vaccine recall

To cap off one of the least effective seasons for flu vaccines in recent memory, vaccine producer GlaxoSmithKline ($GSK) announced the recall of all remaining doses of a quadrivalent, affecting roughly 1.7 million jabs.

GSK recalls vaccine made at troubled plant in Canada

GlaxoSmithKline ($GSK) is recalling 1.7 million doses of its quadrivalent flu vaccine that was manufactured at a plant that ran into a series of manufacturing issues last year including an FDA warning letter. The company says there are questions about whether the vaccine is retaining its potency.

Study: Neuraminidase antibodies help protect against flu

A study from the University of Michigan and the Centers for Disease Control and Prevention has yielded what's being called "convincing" evidence that antibodies to the influenza virus protein neuraminidase (NA) contribute to protection against flu in people who have received a flu shot.

VaxCorps coordinates global vaccine solutions network

PMG Research, Benchmark Research and Miami Research Associates have joined forces to create VaxCorps, a vaccine site network to advance and develop vaccine solutions.
The goal of VaxCorps is to further innovative solutions for the vaccine industry’s practices, reproduction capabilities and standardization through the industry’s large-scale trials. The network will contain experienced clinical research centers located around the world that are dedicated to conducting vaccine trials among diverse populations.

EU agency issues flu-virus vaccine strain directives for 2015-16

Health professionals from the European Medicines Agency (EMA) said on Friday that vaccine manufacturers should include influenza virus strains from this flu season in the vaccine for next season.
The European Union bureau’s recommendations are formulated from observations by the World Health Organization (WHO). The agency said that the trivalent vaccine for the 2015-16 influenza season must include three specific virus strains: an A/Switzerland/9715293/2013 (H3N2)-like virus, a B/Phuket/3073/2013-like virus and an A/California/7/2009 (H1N1)pdm09-like virus.

Annual New Technologies, New Vaccines conference to begin Sunday

World health industry leaders will meet for the 10th Annual New Technologies, New Vaccines conference Sunday through Wednesday in Wilmington, Delaware.
Over 100 business owners, representatives of regulatory agencies and scientists traveled from across the globe to attend the conference. The leaders will exchange their latest discoveries and advancements as they battle against deadly diseases and potential future pandemics like HIV, Ebola and influenza strains.

Discussion topics from Pandemic Influenza, 2nd Edition

Pandemic influenza is a re-emerging disease with serious public health consequences. The H1N1 pandemic in 2009-10 and the continuing threat to humans from avian influenza H5N1 and H5N8 have underlined this threat.
Particularly in an increasingly globalised society, it is essential that we have preparedness plans in please at a local, national and international level.